Display options
Cite
Woo MS, Park J, Ok SH, et al. The proper concentrations of dextrose and lidocaine in regenerative injection therapy: . Korean J Pain. 2021;34(1):19-26doi: 10.3344/kjp.2021.34.1.19.
Woo, M. S., Park, J., Ok, S. H., Park, M., Sohn, J. T., Cho, M. S., Shin, I. W., & Kim, Y. A. (2021). The proper concentrations of dextrose and lidocaine in regenerative injection therapy: . The Korean journal of pain, 34(1), 19-26. https://doi.org/10.3344/kjp.2021.34.1.19
Woo, Min Seok, et al. "The proper concentrations of dextrose and lidocaine in regenerative injection therapy: ." The Korean journal of pain vol. 34,1 (2021): 19-26. doi: https://doi.org/10.3344/kjp.2021.34.1.19
Woo MS, Park J, Ok SH, Park M, Sohn JT, Cho MS, Shin IW, Kim YA. The proper concentrations of dextrose and lidocaine in regenerative injection therapy: . Korean J Pain. 2021 Jan 01;34(1):19-26. doi: 10.3344/kjp.2021.34.1.19. PMID: 33380564; PMCID: PMC7783851.
Copy Download .nbib Format: NLM
Share it on

Korean J Pain. 2021 Jan 01;34(1):19-26. doi: 10.3344/kjp.2021.34.1.19.

The proper concentrations of dextrose and lidocaine in regenerative injection therapy: .

The Korean journal of pain

Min Seok Woo, Jiyoung Park, Seong-Ho Ok, Miyeong Park, Ju-Tae Sohn, Man Seok Cho, Il-Woo Shin, Yeon A Kim

Affiliations

  1. Department of Convergence Medical Science, Gyeongsang National University, Jinju, Korea.
  2. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea.
  3. Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Korea.
  4. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Jinju, Korea.
  5. Department of Anesthesiology and Pain Medicine, Gyeongsang National University College of Medicine, Jinju, Korea.

PMID: 33380564 PMCID: PMC7783851 DOI: 10.3344/kjp.2021.34.1.19

Abstract

BACKGROUND: Prolotherapy is a proliferation therapy as an alternative medicine. A combination of dextrose solution and lidocaine is usually used in prolotherapy. The concentrations of dextrose and lidocaine used in the clinical field are very high (dextrose 10%-25%, lidocaine 0.075%-1%). Several studies show about 1% dextrose and more than 0.2% lidocaine induced cell death in various cell types. We investigated the effects of low concentrations of dextrose and lidocaine in fibroblasts and suggest the optimal range of concentrations of dextrose and lidocaine in prolotherapy.

METHODS: Various concentrations of dextrose and lidocaine were treated in NIH-3T3. Viability was examined with trypan blue exclusion assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Migration assay was performed for measuring the motile activity. Extracellular signal-regulated kinase (Erk) activation and protein expression of collagen I and α-smooth muscle actin (α-SMA) were determined with western blot analysis.

RESULTS: The cell viability was decreased in concentrations of more than 5% dextrose and 0.1% lidocaine. However, in the concentrations 1% dextrose (D1) and 0.01% lidocaine (L0.01), fibroblasts proliferated mildly. The ability of migration in fibroblast was increased in the D1, L0.01, and D1 + L0.01 groups sequentially. D1 and L0.01 increased Erk activation and the expression of collagen I and α-SMA and D1 + L0.01 further increased. The inhibition of Erk activation suppressed fibroblast proliferation and the synthesis of collagen I.

CONCLUSIONS: D1, L0.01, and the combination of D1 and L0.01 induced fibroblast proliferation and increased collagen I synthesis

Keywords: Actins; Cell Migration Assay; Cell Proliferation; Collagen Type 1; Extracellular Signal-Regulated MAP Kinases; Fibroblast; Glucose; Lidocaine; Muscle; Prolotherapy; Smooth

References

  1. Cytotherapy. 2016 Mar;18(3):371-83 - PubMed
  2. Prim Care. 2010 Mar;37(1):65-80 - PubMed
  3. J Cardiovasc Pharmacol. 2015 Aug;66(2):135-40 - PubMed
  4. Gynecol Oncol. 2015 Sep;138(3):668-75 - PubMed
  5. Liver Int. 2005 Oct;25(5):1018-26 - PubMed
  6. PLoS One. 2014 Feb 21;9(2):e89563 - PubMed
  7. Cell Res. 2002 Mar;12(1):9-18 - PubMed
  8. Clin Cosmet Investig Dermatol. 2014 Nov 06;7:301-11 - PubMed
  9. Am J Nephrol. 2003 May-Jun;23(3):129-39 - PubMed
  10. Arch Phys Med Rehabil. 2005 Apr;86(4):697-702 - PubMed
  11. Neural Regen Res. 2014 Jun 15;9(12):1195-203 - PubMed
  12. Anesth Analg. 2014 Jan;118(1):116-24 - PubMed
  13. Cardiovasc Diabetol. 2015 Feb 07;14:18 - PubMed
  14. Biomed Res. 2005 Dec;26(6):231-9 - PubMed
  15. Mol Cell Biochem. 2007 Jul;301(1-2):109-14 - PubMed
  16. PLoS One. 2014 Jul 28;9(7):e103148 - PubMed
  17. Altern Ther Health Med. 2003 May-Jun;9(3):58-62 - PubMed
  18. Sci Rep. 2016 Jan 08;6:18995 - PubMed
  19. Cell Physiol Biochem. 2015;36(6):2093-107 - PubMed
  20. J Anesth. 2012 Feb;26(1):54-61 - PubMed
  21. Am J Sports Med. 2014 Dec;42(12):2888-96 - PubMed
  22. Biochem Biophys Res Commun. 2014 Feb 14;444(3):395-400 - PubMed
  23. J Diabetes Res. 2016;2016:6384759 - PubMed
  24. J Bone Joint Surg Am. 2010 Mar;92(3):609-18 - PubMed

Publication Types